Eisai Deal Puts Epizyme In Position To Advance Lead Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Eisai on epigenetic enzymes is collaborative, whereas in recent tie up with GSK, Epizyme gave up control of development and commercialization of select histone methyltransferases.